Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2002

View Archived Issues

A crossover study provides evidence of the analgesic properties of reboxetine

NC-1900 improves place learning deficits in rats after transient forebrain ischemia

Fumagillin is effective against intestinal microsporidiosis in immunocompromised patients

New PDE4 inhibitors in early development at Merck KGaA

New ERbeta modulators and their use in Alzheimer's, anxiety, osteoporosis, etc.

Novel MCH antagonists covered by Schering-Plough patent

Ishihara Sangyo describes new inhibitors of Th1 and/or Th2 cytokine production

New ACAT inhibitors prepared and tested by Pola researchers

Alkermes and Reliant call off merger

Ovation acquires Tranxene and Desoxyn from Abbott

Aphton seeks E.U. clearance for G17DT trial in GERD

Yamanouchi discontinues YM-175

MT-100 provides significant pain relief in difficult-to-treat migraine patients

Antisoma completes enrollment in phase I TheraFab trial

Xcytrin to enter new phase III trial in NSCLC patients

Ortho Tri-Cyclen Lo receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...